More News

25 August 2020

AbbVie, Harvard University Form Research Alliance to Address Emergent Viral Diseases

25 August 2020

Engitix Signs Collaboration and Licensing Agreement with Takeda to Develop Anti-Fibrotic Therapies in Advanced Liver Diseases

25 August 2020

Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement

24 August 2020

NantKwest and ImmunityBio Sign Collaboration Agreement for Joint Development, Manufacturing, Marketing, and Commercialization of COVID-19 Vaccine and Related Therapeutics

21 August 2020

Sorrento Enters Into Merger Agreement to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic Antibodies, Starting With Neutralizing Antibodies to Treat COVID-19 and Cancer Therapeutics

19 August 2020

Johnson & Johnson to Acquire Momenta Pharmaceuticals, Inc., Expanding Janssen’s Leadership in Novel Treatments for Autoimmune Diseases

18 August 2020

LG Chem Life Sciences and TransThera Biosciences Announce License Agreement for Potential Treatment of NASH and Other Chronic Inflammatory Conditions

18 August 2020

Gilead Sciences and Tango Therapeutics to Expand Strategic Oncology Collaboration

17 August 2020

Dragonfly Therapeutics and Bristol Myers Squibb Announce Exclusive Global License for Dragonfly’s IL-12 Investigational Immunotherapy Program

17 August 2020

Abeona Therapeutics and Taysha Gene Therapies Enter into Licensing and Inventory Purchase Agreements for ABO-202, a Clinical Stage, Novel, One-time Gene Therapy for CLN1 Disease

17 August 2020

Sanofi to acquire Principia Biopharma

12 August 2020

GeneCentric Therapeutics Enters into Research Collaboration with Janssen on Genomic Drug Response Biomarkers for Non-Muscle Invasive Bladder Cancer

11 August 2020

Bayer to Acquire UK-Based Biotech KaNDy Therapeutics Ltd.

11 August 2020

Ligand to Acquire Pfenex Inc.

10 August 2020

Verastem Oncology Signs Definitive Agreement to Sell COPIKTRA® (duvelisib) Rights to Secura Bio to Focus on Development of VS-6766 and Defactinib in KRAS Mutant Solid Tumors

6 August 2020

Biogen and Denali to Collaborate on LRRK2 Program for Parkinson’s Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases

6 August 2020

T-knife Completes €66 Million Series A Financing to Develop Next-Generation T-Cell Therapies

6 August 2020

GentiBio Launches with $20M Seed Funding from OrbiMed, Novartis Venture Fund and RA Capital Management, L.P. to Develop Engineered Regulatory T cells to Deliver Immune Tolerizing Therapies for Autoimmune and Inflammatory Diseases

6 August 2020

Taysha Gene Therapies Announces Oversubscribed $95 Million Series B Financing to Bolster Initial Clinical Studies in GM2 Gangliosidosis and Advance Pipeline of Gene Therapies for Monogenic CNS Disease in Both Rare and Large Patient Populations

6 August 2020

Teva and Alvotech Announce Strategic Partnership to Collaborate in the U.S. Biosimilar Market

4 August 2020

Redx signs out licensing agreement with AstraZeneca

4 August 2020

LUMICKS enters collaboration with Glycostem to enhance NK cell-mediated immunotherapy

30 July 2020

Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders

30 July 2020

Spring Bank Pharmaceuticals and F-star Therapeutics Agree to Combine to Pursue Mission of Creating Next Generation Immunotherapies

29 July 2020

Biotech VICO Therapeutics raises $31 million (€27 million) in Series A financing round to advance therapies for rare central nervous system diseases

29 July 2020

Lilly’s P-tau217 Blood Test Shows High Accuracy in Diagnosis of Alzheimer’s Disease in Data Published in JAMA

28 July 2020

Terns Pharmaceuticals and Hansoh Pharma Announce Collaboration and License Agreement for TRN-000632 in Greater China

28 July 2020

BioTheryX Announces $35 Million Series D Financing

27 July 2020

Lynk Pharmaceuticals enters exclusive licensing agreements with Kobe University and with RIKEN Research Institute to develop RAS inhibitors with a novel MOA

24 July 2020

Sorrento Enters Into Letter Of Intent To Acquire SmartPharm And Develop Pipeline Of Gene-Encoded Therapeutic Antibodies, Starting With Neutralizing Antibodies To Treat COVID-19 and Cancer Therapeutics

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

FcRn Inhibitors Pipeline Review

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review

Bispecific Antibodies for Immuno-Oncology & Other Diseases

Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Ranibizumab (Lucentis) Biosimilars Pipeline Review

Adalimumab (Humira) Biosimilars Pipeline Review